AI
SLS icon

Atom Investors’s SELLAS Life Sciences SLS Stock Holding History

Atom Investors’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-54,624
Closed -$120K – 795
2025
Q2 		$120K Sell
54,624
-9,592
-15% -$14.7K 0.01% 540
2025
Q1 		$69.4K Buy
+64,216
New +$76.2K 0.01% 454

Other funds holding SLS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Atom Investors's SLS Position: Q3 2025 in Review

Atom Investors sold out of SELLAS Life Sciences (SLS) in Q3 2025, closing a stake of 54,624 shares — an estimated $120K sold.

Atom Investors first reported a position in SLS in Q1 2025 and held it in 2 quarters. The position peaked at $120K in Q2 2025. 94 funds tracked by Wall St. Rank hold SLS as of Q3 2025.

  • Atom Investors reported no remaining SELLAS Life Sciences position as of Q3 2025 after selling out during the quarter.
  • Atom Investors sold 54,624 SELLAS Life Sciences shares in Q3 2025, an estimated $120K.
  • Atom Investors first reported a position in SELLAS Life Sciences in Q1 2025 and held it in 2 quarters.
  • Atom Investors's SELLAS Life Sciences position peaked at $120K in Q2 2025.
  • 94 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q3 2025.

Based on Atom Investors's 13F filing for Q3 2025, filed 14 Nov 2025.